Supervisory board

Barend van Doorn (1968) has over a 25 years' track record in the corporate world, serving and advising many Fortune-500 companies. He obtained his business economics degree from the Erasmus University in Rotterdam in 1992. He also obtained a MBA degree at the Kellogg’s North-western University Chicago/ Antwerp Business school in 1996 and in 2014 he completed the International Directors Program (IDP) at INSEAD.

After obtaining his academic degree, he was active in the pharmaceutical retail and wholesale area in the Netherlands, Belgium and Ireland. Furthermore he has owned a number of pharmacies in Belgium for more than 15 years and had participations in various companies. In addition he held various international executive positions at Reuters, Accenture, Genpact and EY in London, USA, Luxembourg and Belgium. From 2008 until 2014 he was partner and member of the board of Accenture Netherlands BV. Subsequently in 2014 he joined Genpact, leading the Managed Services Business & Consulting in Europe. In 2016 he joined EY (Ernst & Young) in the Netherlands to lead the Consulting Practice and joined the Executive Board of EY NL Consulting LLP in 2018. Currently he is still a partner at EY and responsible for Managed Services in Europe West. In 2019 he became the chairman of the Handels-Sociëteit (founded in 1852) in Utrecht. Barend has been a member of CHDR's supervisory board since 2022.

Gerard W.M. van Odijk has over 25 years' track record in the healthcare industry. He obtained his medical degree from Utrecht University. After obtaining his academic degree, he held various international executive positions and a senior position at GlaxoSmithKline (GSK). From 2006 until mid-2012 he served as President and CEO of Teva Pharmaceuticals Europe. Since 2013, he has been an independent healthcare industry advisor. Gerard currently serves as chairman of the board for Bavarian Nordic A/S. He is also a member of the board of Curaeos BV and was until recently chairman of the board of HTL-STREFA SA. Previous to this, he was chairman of Merus NV and Syntarga BV. He also served as non-executive board member for UDG Healthcare PLC, Neurogen A/S and Alvogen SARL. He is a member of the advisory board of the Dutch Medicines Agency and has served as the chairman of the supervisory board of the Hubrecht Organoid Technology (HUB) foundation since 2013. He has been a member of CHDR's supervisory board since 2019.

Jabine van der Meijs (1966) has a background in finance and management. Most recently, she served as the EVP & CFO of the Royal Schiphol Group. Prior to this, she worked for the Royal Dutch Shell Group for 25 years in primarily financial leadership positions in The Netherlands, Scotland, England, Brunei and Australia.

Jabine currently hold various Board positions; She is a member of the Supervisory Board of Kendrion NV and of the Supervisory Board of Koole Terminals Holding BV. She is a member of the Board of Directors of Grundfos Holding A/S, a privately owned Danish Company, and she is a member of the Board of Directors of Pharming Group NV.

Previously, she served on the Boards of Aeroports de Paris (France) and Brisbane Airport Corporation (Australia).

Jabine holds a MSc (Pharmacy) and a Doctor of Pharmacy (Pharm D) degree from the University of Utrecht, and she has professional accounting degree from the UK Chartered Institute of Management Accountants (ACMA/CGMA).

Jabine has been a member of the CHDR Supervisory Board since 2021.

Manuela A. Joore (1971) graduated from Health Policy, Economics and Management in 1996 and received a PhD in Economics in 2002 (Maastricht University). For over 25 years she has been working in the field of Health Technology Assessment. In 2016 she was appointed full professor in 'Health Technology Assessment & Decision-Making' within the research school CAPHRI, Maastricht University. She currently is head of the department of Clinical Epidemiology and Medical Technology Assessment of the Maastricht University Medical Center+. Manuela is/was a member of committees of the Health Council and the Netherlands Organization for Health Research and Development. She leads a health economics evidence review group for the National Institute for Health and Care Excellence NICE) and she is a member of the Methodology Research Panel of the Medical Research Council in the United Kingdom. From 2013 to 2021 she was a member of the scientific advisory board of the Dutch Health Care Institute. Manuela is a founding member and ambassador of Health Innovation Netherlands; a multi-stakeholder infrastructure to contribute to bringing better medical devices to users faster. Her research efforts are focused on health economic evaluation to inform decision making regarding the (further) development and use of health technologies. All with the goal to maximize value for end-users against reasonable costs for all stakeholders, including society at large.

Marianne de Visser (1950) studied medicine at the University of Amsterdam and graduated in 1975. She has been a neurologist since 1980, and obtained her PhD in 1981. From 1982, she worked as a neurologist at the Amsterdam Academic Medical Center and from 2004 to 2016 she also fulfilled an administrative function as Divisional Director. She retired in June 2016. She has been Professor of Neuromuscular Diseases at the University of Amsterdam since 1993. From 1999-2009, she was a board member of the Dutch Organisation for Health Research and Development (ZonMw). She was vice-president of the Health Council of the Netherlands from 2002 to 2010. From 2010 to 2017 she was a member of the General Board of the Dutch Research Council (NWO) and has been a member of the council of the Netherlands' Scientific Council for Government Policy (WRR) since 2013. She is a member of supervisory boards associated with various health organisations. Marianne has been a member of CHDR's supervisory board since 2018.

Present functions

• Chairman of the Supervisory Board of Ipse de Bruggen
• Member Supervisory Board De Hoogstraat, Utrecht
• Member Supervisory Board Martini Hospital, Groningen
• Member Coronacrisis Guidance Committee of the Dutch ‘Onderzoeksraad voor de Veiligheid’
• Member of Supervisory Board University of Amsterdam
• Emeritus Professor at the Department of Medical Microbiology, Leiden University Medical Center
• Chairman of the Quality of Care Care Programme Committee of the Dutch Organisation for Health Research and Development

Training & experience

Willy Spaan was trained as a (molecular) virologist at the University of Utrecht, the Netherlands (graduated in 1980, cum laude). Following his PhD degree (cum laude) in 1984, he was a post-doctoral fellow at the Salk Institute, La Jolla aiming at the development of a recombinant DNA vaccines. In 1986 he was appointed as head of the Molecular Virology unit of the Faculty of Veterinary Medicine and in 1990 he moved to the Leiden University Medical Center (LUMC) where he became full professor and chairman at the department of Medical Microbiology. In 1997 he co-founded the Center of Infectious Diseases and in 2001 he moved part-time into the LUMC administration as chairman of one of the LUMC divisions. In 2008 he became chairman of the Executive Board of the Jeroen Bosch Hospital. Since 1996 untill 2010 he was an active member of the executive board of Dutch Organisation for Health Research and Development and was for several years a representative of the Dutch Health Research Council for the European Union Research Framework Programme. From May 2015 until July 2020 he was the chair of the Executive Board of the Leiden University Medical Center. In 2018 till June 2020 he was chairman of the Netherlands Association of University Medical Centers. Currently he is amongst others (vice)-chairman of several supervisory boards of different (Health) Institutions in the Netherlands and of the University of Amsterdam.